Home >> WEBINARS >> IGHV clinical utility in CLL and preferred testing practices

IGHV clinical utility in CLL and preferred testing practices

Print Friendly, PDF & Email

Thursday, February 28, 2019, 1PM–2PM ET

Dr. Hanson

Webinar presenter Curtis A. Hanson, MD, Professor of Laboratory Medicine and Pathology Mayo Clinic College of Medicine, Rochester, Minnesota, will review the role of key High Risk (HR) biomarkers in CLL, focusing on clinical evidence and raising awareness for IGHV mutation status as an important CLL biomarker that can help guide treatment decisions. Webinar will also provide best practices for how and when to request IGHV testing and how to perform testing for IGHV mutation status in CLL patients. Ask your questions of our distinguished presenter.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY


  • Describe testing algorithm inclusive of IGHV mutation status determination at initial diagnostic work up for all CLL patients that can support first line treatment decisions, since it is a powerful predictor of duration of response and overall survival with chemoimmunotherapy (CIT)
  • Show that depending upon a patient’s IGHV mutation status, alternative treatment strategies may be a more suitable option versus CIT
  • Demonstrate IGHV mutation status testing should be incorporated into comprehensive CLL panels with other important CLL HR prognostic and predictive markers for all newly diagnosed CLL patients
  • Preferable that IGHV mutation status is determined directly using a molecular method versus indirect Flow or IHC based methods that test surrogate markers.
Register Now

CAP TODAY does not endorse any of the products or services named within.
The webinar is made possible by a special educational grant from Diaceutics.